Synthetic cannabinoids (SCs), commonly marketed as “Spice” and “K2”, are potent new psychoactive compounds being used among high school students, with a high risk of adverse health outcomes. Some compounds found in SCs resemble those in marijuana and are often marketed as being similar. In reality, SCs have been found to have a potency ranging from 2 to 100 times stronger than marijuana, making adverse health outcomes of SC use exponentially greater than marijuana use.
“This was the first national study examining current use of these new compounds among high school students. It’s essential to investigate those who are current users rather than ‘ever-users’ in order to understand who is currently at risk for adverse outcomes,” said Joseph Palamar, PhD, MPH, a researcher at New York University Rory Meyers College of Nursing’s Center for Drug Use and HIV Research (NYU CDUHR).
To counter the paucity of research in this area of high school drug use, Dr. Palamar and his team conducted the first nationally representative study, published in the journal Pediatrics, in which current (past 30-day) use of SCs was examined. In this study, they found that 3% of high school seniors reported current use, with nearly half of these users reporting use more than 3 times in the past month.
“This finding is important because it implies that half of current users are using SCs more than once or twice, which may suggest more than just mere experimentation,” said Dr. Palamar, also an assistant professor of Population Health at NYU Langone Medical Center (NYULMC). “In fact, 20% of current users reported use on 20 to 30 days in the past month, suggesting daily or almost-daily use.”
“The fact that one-fifth of current adolescent SC users report using these drugs in a daily or almost daily basis is of concern,” notes Dr. Silvia Martins, MD, PhD, senior author on the study and an associate professor of epidemiology at Columbia University’s Department of Epidemiology. “This is particularly notable due to all possible adverse effects associated with SC use.”
Dr. Palamar’s article, “Synthetic Cannabinoid Use Among High School Seniors,” draws data from Monitoring the Future, a nationwide ongoing annual study of the behaviors, attitudes, and values of American secondary school students. The survey is administered in approximately 130 public and private schools throughout 48 states in the US. Roughly 15,000 high school seniors are assessed annually.
“Males, African Americans, and users of various other drugs were found to be at particular risk for frequent SC use,” said co-author Monica J. Barratt, PhD, Drug Policy Modelling Program, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia.
SC use is closely tied to marijuana use, as 8 out of 10 current SC users also reported current marijuana use. Therefore, the authors compared current SC users who were also current marijuana users to the “marijuana-only” users who did not report current SC use.
Findings from the study revealed that compared to marijuana-only users, fewer SC users perceived that SC experimentation and occasional use placed themselves at great risk of harm. SC users were more likely than marijuana-only users to report high perception of risk of using marijuana occasionally. Implications of this finding show a potential for lack of knowledge about health risks of SC among its youngest users.
“If there are students using synthetic cannabinoids because they genuinely believe they are less risky than marijuana, this misconception must be addressed through better education stressing the greater danger posed by synthetic cannabinoids,” said Dr. Palamar.
In addition, pointing to the fact that many SCs are not (yet) illegal, Dr. Palamar notes “some students may deem real marijuana as a riskier substance because it is illegal to possess. While arrest should in fact be a concern for marijuana users, these new synthetic compounds are becoming too dangerous and are in no way a safe alternative to marijuana.”
Current SC users also tend to be current users of other drugs.
“Concurrent use of other drugs such as alcohol can make adverse outcomes more likely,” stresses Dr. Palamar. “Our findings help allow clinicians and public health experts to determine who is at risk for SC use and possibly poisoning from SC use, so appropriate directed intervention education measures can be deployed.”
“Evolving generations of SC compounds are increasingly harmful and poisonous to overall health, making effective prevention efforts more important than ever,” explained Dr. Barratt.
Although previous studies have revealed that marijuana users are at high risk for SC use, this study further revealed risk factors among current marijuana users that increase risk of current use and higher-frequency use of SCs.
“Our research calls for future prevention focused primarily on marijuana users, especially male and/or African American marijuana users who appear to be at greatest risk for frequent use,” said Dr. Palamar. “Marijuana users who use other drugs are at highest risk for currently using SCs, so particular focus must be paid to these individuals to prevent increasingly dangerous and severe health outcomes among young users.”
Joseph J. Palamar, PhD, MPH, a
Monica J. Barratt, BSc(Hons), PhD, b, c, d
Leigh Coney, BSc, PGDip, b
Silvia S. Martins, MD, PhD e
a Department of Population Health, Langone Medical Center, New York University, New York, New York;
b Drug Policy Modelling Program, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia;
c National Drug Research Institute, Faculty of Health Sciences, Curtin University, Bentley, Australia;
d Behaviours and Health Risks Program, Burnet Institute, Melbourne, Australia; and
e Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York
Financial Disclosure: The authors have indicated they have no financial relationships relevant to this article to disclose.
Funding: Research reported in this publication was supported by the National Institute on Drug Abuse of the National Institutes of Health under award K01DA038800 (principal investigator: Palamar). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The Inter-university Consortium for Political and Social Research and Monitoring the Future principal investigators also had norole in analysis, interpretation of results, or in the decision to submit this manuscript. This project was also supported by R01DA037866 (Martins), and Barratt is supported by a fellowship from the National Health and Medical Research Council (APP1070140). The National Drug and Alcohol Research Centre and the National Drug Research Institute are supported by funding from the Australian government under the Substance Misuse Prevention and Service Improvement Grants Fund. Funded by the National Institutes of Health (NIH).
Potential Conflict of Interest: The authors have indicated they have no potential conflicts of interest to disclose.
The mission of the Center for Drug Use and HIV Research (CDUHR) is to end the HIV and HCV epidemics in drug using populations and their communities by conducting transdisciplinary research and disseminating its findings to inform programmatic, policy, and grass roots initiatives at the local, state, national and global levels. CDUHR is a Core Center of Excellence funded by the National Institute on Drug Abuse (Grant #P30 DA011041). It is the first center for the socio-behavioral study of substance use and HIV in the United States and is located at the New York University College of Nursing. For more information, visit www.cduhr.org.
About NYU Langone Medical Center
NYU Langone Medical Center, a world-class, patient-centered, integrated academic medical center, is one of the nation’s premier centers for excellence in clinical care, biomedical research, and medical education. Located in the heart of Manhattan, NYU Langone is composed of four hospitals—Tisch Hospital, its flagship acute care facility; Rusk Rehabilitation; the Hospital for Joint Diseases, the Medical Center’s dedicated inpatient orthopaedic hospital; and Hassenfeld Children’s Hospital, a comprehensive pediatric hospital supporting a full array of children’s health services across the Medical Center—plus the NYU School of Medicine, which since 1841 has trained thousands of physicians and scientists who have helped to shape the course of medical history. The Medical Center’s tri-fold mission to serve, teach, and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education, and research. For more information, go to www.NYULMC.org,
About the NYU Rory Meyers College of Nursing
NYU Rory Meyers College of Nursing is a global leader in nursing education, research, and practice. It offers a Bachelor of Science with a major in Nursing, a Master of Science and Post-Master’s Certificate Programs, a Doctor of Nursing Practice degree and a Doctor of Philosophy in nursing research and theory development.